Nymozarfex Now Available for Prostate Treatment in the Caribbean

Nymox Pharmaceutical Corporation has announced a collaboration with the Global Alliance of Regenerative Medicine (GARM) to offer its Nymozarfex treatment for prostate conditions on Roatan Island, Caribbean. This partnership enables medical tourists to access this treatment in a cutting-edge facility. Nymozarfex is designed for men seeking alternatives to current prostate enlargement treatments, which often have undesirable side effects and surgical risks. The drug will be administered by certified urologists without the need for anesthesia, offering a safer option for prostate health management.

Nymox CEO Paul Averback highlighted the significance of providing more viable options for men with prostate issues. The launch of Nymozarfex in a licensed facility aims to offer patients a choice while maintaining healthcare standards from their home countries. This initiative marks a strategic effort by Nymox to enhance prostate care options beyond traditional medicines and surgeries.